RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

por Manzano, Ramon Gonzalez, Catalan-Latorre, Ana, Brugarolas, Antonio
Publicado 2021

Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study

por Escudero-Ortiz, Vanesa, Domínguez-Leñero, Vanessa, Catalán-Latorre, Ana, Rebollo-Liceaga, Joseba, Sureda, Manuel
Publicado 2022